Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Azenta ( (AZTA) ).
On March 4, 2026, Azenta announced that its subsidiary Azenta UK Ltd had completed the acquisition of UK Biocentre Limited, a UK-based provider of sample management, storage and high-throughput processing services, for total consideration of GBP 20.5 million, including up to GBP 1.8 million in contingent payments. Founded in 2014, UK Biocentre generated about GBP 15.3 million in revenue in the 12 months to September 30, 2025 and will continue operating under its existing name.
The deal is designed to expand Azenta’s biorepository and sample management footprint in Europe by using UK Biocentre as a regional operational hub complementing its Griesheim, Germany facility and serving pharmaceutical, biotech, academic and public health clients. Azenta expects the transaction to be modestly dilutive to its 2026 adjusted EBITDA margin by about 35 basis points but accretive to organic revenue growth and margin expansion in 2027 and 2028, while enhancing its ability to deliver large-scale, automated biorepository capabilities such as the 16-million-sample BioArc Ultra platform and reinforcing its positioning at the center of key life sciences workflows.
The most recent analyst rating on (AZTA) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.
Spark’s Take on AZTA Stock
According to Spark, TipRanks’ AI Analyst, AZTA is a Neutral.
AZTA’s score is driven primarily by solid financial stability (low leverage and currently positive cash flow) and reaffirmed guidance supporting a margin-improvement narrative. These positives are weighed down by a very weak technical setup (stock below all major moving averages with bearish momentum) and ongoing profitability challenges, with near-term margin pressure highlighted on the earnings call.
To see Spark’s full report on AZTA stock, click here.
More about Azenta
Azenta, Inc., headquartered in Burlington, Mass., is a leading global provider of life sciences solutions, offering cold-chain sample management and multiomics services that support drug development, clinical research and advanced cell therapies. The company serves major pharmaceutical, biotechnology, academic and healthcare institutions worldwide through brands including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro and Barkey.
Azenta operates across North America, Europe and Asia, focusing on enabling customers to bring new therapies and scientific breakthroughs to market more quickly. Its portfolio spans end-to-end sample lifecycle management and genomic services, positioning the company as a key infrastructure and technology partner in the life sciences ecosystem.
Average Trading Volume: 772,111
Technical Sentiment Signal: Sell
Current Market Cap: $1.13B
See more data about AZTA stock on TipRanks’ Stock Analysis page.